Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

ANI Pharma Inc (ANIP)

ANI Pharma Inc (ANIP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 543,884
  • Shares Outstanding, K 17,247
  • Annual Sales, $ 216,140 K
  • Annual Income, $ -42,600 K
  • 60-Month Beta 1.01
  • Price/Sales 2.37
  • Price/Cash Flow 6.29
  • Price/Book 1.59
Trade ANIP with:

Options Overview Details

View History
  • Implied Volatility 63.70% ( -6.91%)
  • Historical Volatility 69.33%
  • IV Percentile 31%
  • IV Rank 23.05%
  • IV High 125.54% on 05/09/22
  • IV Low 45.17% on 08/31/21
  • Put/Call Vol Ratio 0.13
  • Today's Volume 86
  • Volume Avg (30-Day) 54
  • Put/Call OI Ratio 0.94
  • Today's Open Interest 1,418
  • Open Int (30-Day) 1,637

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate 0.04
  • Number of Estimates 2
  • High Estimate 0.13
  • Low Estimate -0.05
  • Prior Year 0.49
  • Growth Rate Est. (year over year) -91.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.31 +41.35%
on 06/16/22
31.87 -1.06%
on 07/01/22
+1.01 (+3.33%)
since 06/01/22
3-Month
22.31 +41.35%
on 06/16/22
33.93 -7.06%
on 04/21/22
+2.85 (+9.95%)
since 04/01/22
52-Week
22.31 +41.35%
on 06/16/22
60.23 -47.64%
on 11/01/21
-4.46 (-12.38%)
since 07/01/21

Most Recent Stories

More News
ANI (ANIP) Soars 6.2%: Is Further Upside Left in the Stock?

ANI (ANIP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

ANIP : 31.53 (+6.29%)
DTIL : 1.5300 (-4.38%)
Veeva Systems (VEEV) Inks Deal to Serve Rare Disease Patients

Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.

OMCL : 115.37 (+1.42%)
AMN : 114.73 (+4.58%)
ANIP : 31.53 (+6.29%)
VEEV : 204.11 (+3.07%)
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Clorazepate Dipotassium Tablets USP

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA)...

ANIP : 31.53 (+6.29%)
ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients

/PRNewswire/ -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) and Veeva Systems (NYSE: VEEV) today announced a collaboration to define and operationalize...

ANIP : 31.53 (+6.29%)
VEEV : 204.11 (+3.07%)
ANI Pharmaceuticals Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium Acquisition

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it intends to cease operations at its Oakville, Ontario, Canada manufacturing plant by first quarter 2023. This action...

ANIP : 31.53 (+6.29%)
ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (“FDA”) approval for the Abbreviated New Drug Application...

ANIP : 31.53 (+6.29%)
ANI Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at two upcoming conferences...

ANIP : 31.53 (+6.29%)
ANI Pharmaceuticals (ANIP) Reports Q1 Loss, Misses Revenue Estimates

ANI (ANIP) delivered earnings and revenue surprises of -250% and 1.56%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ANIP : 31.53 (+6.29%)
SRRK : 5.33 (-2.91%)
ANI Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Full-Year 2022 Total Company Net Revenue Guidance of $295 Million to $315 Million

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three months ended March 31, 2022.

ANIP : 31.53 (+6.29%)
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -26.87% and 8.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ALIM : 5.46 (-0.18%)
ANIP : 31.53 (+6.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone...

See More

Key Turning Points

3rd Resistance Point 35.36
2nd Resistance Point 33.61
1st Resistance Point 32.57
Last Price 31.53
1st Support Level 29.79
2nd Support Level 28.05
3rd Support Level 27.01

See More

52-Week High 60.23
Fibonacci 61.8% 45.74
Fibonacci 50% 41.27
Fibonacci 38.2% 36.79
Last Price 31.53
52-Week Low 22.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar